Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Clinical trial NCT06297603 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06297603
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-15
- Primary completion
- 2026-10-01
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.